

RECEIVED
CENTRAL FAX CENTER
JUL 02 2008

PATENT APPLN. NO. 10/534,874
SUBMISSION UNDER 37 C.F.R. §1.114

PATENT
NON-FINAL

IN THE CLAIMS:

1. (currently amended) A liposome to which a polyalkylene glycol and wild type human serum albumin are bonded ~~selected from the group consisting of:~~

~~(a) a liposome to which each of a polyalkylene glycol and a non-modified serum albumin is bonded, wherein the non-modified serum albumin is bonded to the liposome via a reactive intervening group;~~

~~(b) a liposome to which a serum albumin is bonded via a polyalkylene glycol, wherein the serum albumin is bonded to the polyalkylene glycol via a reactive intervening group; and~~

~~(c) a liposome wherein the liposome and a polyalkylene glycol are bonded to a serum albumin via reactive intervening groups at a different site.~~

2. (original) The liposome according to claim 1, wherein a physiologically active ingredient is further contained.

3. (original) The liposome according to claim 2, wherein the physiologically active ingredient is a pharmaceutically active ingredient.

4. (original) The liposome according to claim 3, wherein the pharmaceutically active ingredient is an antitumor agent.

5. (currently amended) A pharmaceutical composition containing the liposome mentioned recited in claim 2.


6. (previously presented) The pharmaceutical composition according to claim 5, wherein the composition is in an injection form.

7. (currently amended) A method for treatment of cancer, which comprises administering a pharmaceutical composition comprising a liposome to which a polyalkylene glycol and wild type human serum albumin are bonded and in which an antitumor agent is contained.

8. (currently amended) A method of extending the in vivo retention time of a physiologically active ingredient contained in a liposome comprising binding the liposome to a polyalkylene glycol and wild type human serum albumin.

9. (currently amended) A process for the production of the liposome comprising a step selected from the group consisting of (A), (B), (C), (D), (E) and (F):[[,]]


(A) ~~a step of bonding a liposome having~~ containing a compound represented by the following formula (1):




(1)

(wherein R is an acyl group derived from a fatty acid having 2 to 35 carbon atoms) and 1,2-distearol-*sn*-glycero-3-phosphoethanolamine bonded to a polyalkylene glycol (PEG-DSPE) as constituent lipids to wild type human serum albumin;

(B) ~~a step of bonding a liposome having~~ containing a compound represented by the following formula (2):




(wherein R has the same meaning as defined above) and 1,2-distearol-*sn*-glycero-3-phosphoethanolamine bonded to a polyalkylene glycol (PEG-DSPE) as constituent lipids to a compound represented by the formula (3):




(wherein Alb-NH is a group formed by removing one hydrogen atom of the amino group from [[an]] a wild type human serum albumin molecule represented by Alb-NH₂);

(C) ~~a step of bonding a liposome having~~ containing a compound represented by the following formula (4):




$$(\text{Alb-NH})-\text{CO}-\text{CH}_2-\text{SH} \quad (5)$$

(D) ~~a step of bonding~~ incorporating a compound represented by the following formula (6):




(E) ~~a step of~~ bonding a liposome having containing the compound represented by the above formula (1) as a constituent lipid to a compound represented by the following formula (7):



(7)

(wherein $-\text{NH-Alb-NH}_2$ is a group formed by removing one hydrogen atom from one of the amino groups of an albumin molecule represented by $\text{H}_2\text{N-Alb-NH}_2$, and n has the same meaning as defined above); or

(F) ~~a step of~~ bonding a liposome having containing the compound represented by the above formula (2) as a constituent lipid to a compound represented by the following formula (8):



(8)

(wherein -NH-Alb-NH- is a group formed by removing one hydrogen atom from each of the two amino groups of an albumin molecule represented by the formula $H_2N-Alb-NH_2$, and n has the same meaning as defined above).

10. (previously presented) A pharmaceutical composition containing the liposome mentioned in claim 3.

11. (previously presented) A pharmaceutical composition containing the liposome mentioned in claim 4.

12. (previously presented) The pharmaceutical composition according to claim 10, wherein the composition is in an injection form.

13. (previously presented) The pharmaceutical composition according to claim 11, wherein the composition is in an injection form.

14. - 16. (canceled)